Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1969 1
1970 1
1974 3
1977 3
1978 1
1980 2
1981 1
1982 2
1983 1
1984 3
1986 1
1987 1
1988 1
1989 1
1990 2
1991 1
1992 1
1993 1
1994 2
1998 2
1999 1
2001 1
2002 1
2003 3
2006 1
2007 3
2012 3
2013 1
2014 2
2016 1
2017 2
2018 1
2019 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
The porphyrias: advances in diagnosis and treatment.
Balwani M, Desnick RJ. Balwani M, et al. Blood. 2012 Nov 29;120(23):4496-504. doi: 10.1182/blood-2012-05-423186. Epub 2012 Jul 12. Blood. 2012. PMID: 22791288 Free PMC article. Review.
These advances include DNA-based diagnoses for all the porphyrias, new understanding of the pathogenesis of the acute hepatic porphyrias, identification of the iron overload-induced inhibitor of hepatic uroporphyrin decarboxylase activity that causes the most common porphyria …
These advances include DNA-based diagnoses for all the porphyrias, new understanding of the pathogenesis of the acute hepatic porphyrias, id …
The porphyrias: advances in diagnosis and treatment.
Balwani M, Desnick RJ. Balwani M, et al. Hematology Am Soc Hematol Educ Program. 2012;2012:19-27. doi: 10.1182/asheducation-2012.1.19. Hematology Am Soc Hematol Educ Program. 2012. PMID: 23233556 Review.
These advances include DNA-based diagnoses for all the porphyrias, new understanding of the pathogenesis of the acute hepatic porphyrias, identification of the iron overload-induced inhibitor of hepatic uroporphyrin decarboxylase activity that causes the most common porphyria …
These advances include DNA-based diagnoses for all the porphyrias, new understanding of the pathogenesis of the acute hepatic porphyrias, id …
Porphyria cutanea tarda: treatment options revisited.
Poh-Fitzpatrick MB. Poh-Fitzpatrick MB. Clin Gastroenterol Hepatol. 2012 Dec;10(12):1410-1. doi: 10.1016/j.cgh.2012.09.005. Epub 2012 Sep 13. Clin Gastroenterol Hepatol. 2012. PMID: 22982098 No abstract available.
Treatment of the porphyrias.
Kauppinen R, Timonen K, Mustajoki P. Kauppinen R, et al. Ann Med. 1994 Feb;26(1):31-8. doi: 10.3109/07853899409147324. Ann Med. 1994. PMID: 7909442 Review.
Pathogenic mechanisms and symptoms differ greatly in individual porphyrias and, consequently, most of them require a specific therapy. Clinically, the three most important entities are acute porphyric attack, porphyria cutanea tarda and protoporphyria. …
Pathogenic mechanisms and symptoms differ greatly in individual porphyrias and, consequently, most of them require a specific therapy …
The management of porphyria cutanea tarda.
Sarkany RP. Sarkany RP. Clin Exp Dermatol. 2001 May;26(3):225-32. doi: 10.1046/j.1365-2230.2001.00825.x. Clin Exp Dermatol. 2001. PMID: 11422163 Review.
Porphyria cutanea tarda (PCT), the commonest of all porphyrias, is usually characterized by blisters and fragility of skin in light-exposed areas. It can be clinically indistinguishable from other disorders including variegate porphyria and the diagnos …
Porphyria cutanea tarda (PCT), the commonest of all porphyrias, is usually characterized by blisters and fragility of s …
Blistering disorders: diagnosis and treatment.
Yeh SW, Ahmed B, Sami N, Razzaque Ahmed A. Yeh SW, et al. Dermatol Ther. 2003;16(3):214-23. doi: 10.1046/j.1529-8019.2003.01631.x. Dermatol Ther. 2003. PMID: 14510878 Review.
A brief review is presented of the following bullous diseases: pemphigus, paraneoplastic pemphigus, bullous pemphigoid, cicatricial pemphigoid, epidermolysis bullosa acquisita, dermatitis herpetiformis, linear IgA bullous disease, porphyria cutanea tarda, and …
A brief review is presented of the following bullous diseases: pemphigus, paraneoplastic pemphigus, bullous pemphigoid, cicatricial pemphigo …
Hepatitis C Treatment in Patients With Porphyria Cutanea Tarda.
Singal AK, Venkata KVR, Jampana S, Islam FU, Anderson KE. Singal AK, et al. Am J Med Sci. 2017 Jun;353(6):523-528. doi: 10.1016/j.amjms.2017.03.007. Epub 2017 Mar 8. Am J Med Sci. 2017. PMID: 28641714 Free PMC article.
BACKGROUND: Hepatitis C virus (HCV) infection is a common susceptibility factor for porphyria cutanea tarda (PCT). Experience on HCV treatment in patients with PCT is limited. ...To prevent PCT recurrence, hydroxychloroquine was continued during HCV therap …
BACKGROUND: Hepatitis C virus (HCV) infection is a common susceptibility factor for porphyria cutanea tarda (PCT). Expe …
Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era.
Wiznia LE, Laird ME, Franks AG Jr. Wiznia LE, et al. J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1260-1270. doi: 10.1111/jdv.14186. Epub 2017 Mar 29. J Eur Acad Dermatol Venereol. 2017. PMID: 28252812 Review.
In addition to highlighting the new treatment options, we review four classically HCV-associated dermatologic disorders - mixed cryoglobulinaemia (MC), lichen planus (LP), porphyria cutanea tarda (PCT) and necrolytic acral erythema (NAE) - and examine the rol …
In addition to highlighting the new treatment options, we review four classically HCV-associated dermatologic disorders - mixed cryoglobulin …
Relapse of porphyria cutanea tarda after treatment with phlebotomy or 4-aminoquinoline antimalarials: a meta-analysis.
Salameh H, Sarairah H, Rizwan M, Kuo YF, Anderson KE, Singal AK. Salameh H, et al. Br J Dermatol. 2018 Dec;179(6):1351-1357. doi: 10.1111/bjd.16741. Epub 2018 Jul 26. Br J Dermatol. 2018. PMID: 29750336 Free PMC article.
BACKGROUND: Porphyria cutanea tarda (PCT) is the most common human porphyria. It is caused by hepatic deficiency of uroporphyrinogen decarboxylase activity, which is acquired in the presence of multiple susceptibility factors. ...
BACKGROUND: Porphyria cutanea tarda (PCT) is the most common human porphyria. It is caused by hepatic deficiency …
Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C.
Bonkovsky HL, Rudnick SP, Ma CD, Overbey JR, Wang K, Faust D, Hallberg C, Hedstrom K, Naik H, Moghe A, Anderson KE. Bonkovsky HL, et al. Dig Dis Sci. 2023 Jun;68(6):2738-2746. doi: 10.1007/s10620-023-07859-8. Epub 2023 Feb 22. Dig Dis Sci. 2023. PMID: 36811718 Free PMC article.
BACKGROUND AND AIMS: Chronic hepatitis C [CHC] is a risk factor for porphyria cutanea tarda [PCT]. To assess whether ledipasvir/sofosbuvir is effective for treating both PCT and CHC, we treated patients with CHC + PCT solely with ledipasvir/sofosbuvir and fol …
BACKGROUND AND AIMS: Chronic hepatitis C [CHC] is a risk factor for porphyria cutanea tarda [PCT]. To assess whether le …
54 results